patients

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each…

1 day ago

2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries

AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging…

1 day ago

James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon

NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its two global winners, each receiving £30,000 for solving…

3 days ago

Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban

November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at the American Heart Association Scientific Sessions show a…

4 days ago

James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon

NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its two global winners, each receiving £30,000 for solving…

4 days ago

James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon

NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its two global winners, each receiving £30,000 for solving…

4 days ago

Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban

November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at the American Heart Association Scientific Sessions show a…

4 days ago

James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon

NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its two global winners, each receiving £30,000 for solving…

5 days ago

James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon

NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its two global winners, each receiving £30,000 for solving…

5 days ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq:…

5 days ago
Show more Posts